ZYME
Zymeworks Inc.stockNASDAQ
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company's novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 26.47 | 2026-11-12 | -1.59% | -0.327 |
| 1M | 25.54 | 2026-10-19 | +2.00% | 1.145 |
| 3M | 27.21 | 2026-08-19 | -4.26% | 1.145 |
| 6M | 24.40 | 2026-05-19 | +6.76% | 0.978 |
| 1Y | 22.60 | 2025-11-19 | +15.27% | 0.910 |
| 2Y | 14.77 | 2024-11-19 | +76.37% | — |
| 5Y | 19.81 | 2021-11-19 | +31.50% | 0.918 |
Zymeworks Inc. (NASDAQ:ZYME) stock price today is $26.05, and today's volume is 1,085,751. ZYME is up 0.813% today. The 30 day average volume is 1.31M. ZYME market cap is $1.83B with 70.12M shares outstanding.
